Piper ‘confident’ partner or buyer will see benefit of Aslan’s eblasakimab

Piper Sandler says the firm is “confident” that a partner or potential acquirer will see the value and differentiation of monthly eblasakimab versus every other week Dupixent, including in the growing patient population of Dupixent inadequate responders, and expects a partner or potential acquirer will likely develop eblasakimab in other allergic indications beyond atopic dermatitis, or AD, such as COPD. The firm reiterates an Overweight rating and $15 price target on Aslan Pharmaceuticals after the company announced that it has begun to enroll patients in the U.S. under an updated protocol in the ongoing TREK-DX trial, studying eblasakimab in dupilumab-experienced patients with moderate-to-severe AD.